A trojan horse in drug development: Targeting of thapsigargins towards prostate cancer cells

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 276-294

  Christensen, S Brøgger ^a   Mondrup Skytte, Dorthe ^a   Denmeade, Samuel R ^b   Dionne, Craig ^c   Møller, Jesper Vuust ^d   Nissen, Poul ^d   Isaacs, John T ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GenSpera   (United States)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

hK2; Prodrug; Prostate cancer; PSA; SERCA; Targeted drugs; Thapsigargin

Indexed keywords

CALCIUM ION; CYTOTOXIC AGENT; DOXORUBICIN; LACTONE; PRODRUG; PROSTATE ANTIGEN; THAPSIGARGIN DERIVATIVE; TRILOBOLIDE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DEACYLATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME RELEASE; HISTAMINE RELEASE; HUMAN; LIPOPHILICITY; NONHUMAN; PROSTATE CANCER; REVIEW; STRUCTURE ACTIVITY RELATION; TARGET CELL DESTRUCTION;

EID: 65549138953     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909030276     Document Type: Review

References (93)

1. Denmeade, S.R.; Isaacs, J.T. The SERCA pump as a therapeutic target. Making a smart bomb for prostate cancer. Cancer Biol. Ther., 2005, 4(1), e69-e77.
2. Isaacs, J.T. New strategies for the medical treatment of prostate cancer. BJU Intern., 2005, 96(Suppl 2), 35-40.
3. Christensen, S.B.; Andersen, A.; Smitt, U.W. Sesquiterpenoids from thapsia species and medicinal chemistry of the thapsigargins. Progr. Chem. Natl. Prod., 1997, 71(1), 131-167.
4. Nelen, V. Epidemiology of prostate cancer. Recent Results Cancer Res., 2007, 175(1), 1-8.
5. Stanford, J.L.; Stephenson, R.A.; Coyle, L.M.; Cerhan, J.; Correa, R.; Eley, J.W.; Gilliland, F.; Hankey, B.; Kolonel, L.N.; Kosary, C.; Ross, R.; Severson, R.; West, D. In Incidence and mortality, National Cancer Institute. NIH Pub. No. 99-4543.: Bethesda, Maryland, 1999, Vol. 1, pp. 7-15.
6. Coldman, A.J.; Phillips, N.; Pickles, T.A. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. Can. Med. Assoc. J., 2003, 168(1), 31-35.
7. Gronberg, H. Prostate cancer epidemiology. Lancet, 2003, 361(9360), 859-864.
8. Singh, P.; Williams, S.A.; Shah, M.H.; Lectka, T.; Pritchard, G.J.; Isaacs, J.T.; Denmeade, S.R. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Prot. Struct. Funct. Bioinform., 2008, 70(4), 1416-1428.
9. Frydenberg, M.; Stricker, P.D.; Kaye, K.W. Prostate cancer diagnosis and management. Lancet, 1997, 349(9066), 1681-1687.
10. Reynolds, M.A.; Kastury, K.; Groskopf, J.; Schalken, J.A.; Rittenhouse, H. Molecular markers for prostate cancer. Cancer Lett., 2007, 249(1), 5-13.
11. Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol., 2005, 100(1-2), 72-79.
12. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70(3), 461-477.
13. Arcamone, F.M. In Anthracyclines, Cragg, G.M.; Kingston, D.G.; Newman, D.J., Eds.; Taylor and Francis: London, 2005, Vol. 1, pp. 299-320.
14. Kingston, D.G. In Taxol and its analogs, Cragg, G.M.; Kingston, D.G.; Newman, D.J., Eds.; Taylor and Francis: London, 2005, Vol. 1, pp. 89-122.
15. Lee, K.-H.; Xiao, Z. In Podophyllotoxins and analogs, Cragg, G.M.; Kingston, D.G.; Newman, D.J., Eds.; Taylor and Francis: London, 2005, Vol. 1, pp. 71-87.
16. Guéritte, F.; Fahy, J. In The vinca alkaloids, Cragg, G.M.; Kingston, D.G.; Newman, D.J., Eds.; Taylor and Francis: London, 2005, Vol. 1, pp. 123-135.
17. Berges, R.R.; Vukanovic, J.; Epstein, J.I.; CarMichel, M.; Cisek, L.; Johnson, D.E.; Veltri, R.W.; Walsh, P.C.; Isaacs, J.T. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1995, 1(5), 473-480.
18. Pinski, J.; Parikh, A.; Bova, G.S.; Isaacs, J.T. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res., 2001, 61(17), 6372-6376.
19. Denmeade, S.R.; Jakobsen, C.M.; Janssen, S.; Khan, S.R.; Garrett, E.S.; Lilja, H.; Christensen, S.B.; Isaacs, J.T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst., 2003, 95(13), 990-1000.
20. Tutin, T.G.; Heywood, V.H.; Burges, N.A.; Moore, D.M.; Valentine, D.H.; Walter, S.M.;Webb, D.A. Flora Europea, Cambridge University Press, 1968.
21. Pujadas-Salva, A.J.; Plaza-Arregui, L. Studies on Thapsia (Apiaceae) from north-western Africa: a forgotten and a new species. Bot. J. Linnean Soc., 2003, 143(4), 433-442.
22. Pujadas, A.; Rossello, J.A. In Real Jardin Botanica. Nielto Feliner, G.; Jury, S.L.; Herrerro, A., Eds.; CSIC: Madrid, 2003, Vol. 10, pp. 401-410.
23. Smitt, U.W. A chemotaxonomic investigation of Thapsia villosa L., Apiaceae (Umbelliferae). Bot. J. Linnean Soc., 1995, 119(4), 367-377.
24. Christensen, S.B.; Norup, E.; Rasmussen, U.; Madsen, J.Ø. Structure of Histamine Releasing Guaianolides from Thapsia Species. Phytochemistry, 1984, 23(8), 1659-1663.
25. Toyoshima, C.; Nomura, H. Structural changes in the calcium pump accompanying the dissociation of calcium. Nature, 2002, 418(6898), 605-611.
26. Andrews, S.P.; Tait, M.M.; Ball, M.; Ley, S.V. Design and total synthesis of unnatural analogues of the sub-nanomolar SERCA inhibitor thapsigargin. Org. Biomol. Chem., 2007, 5(9), 1427-1436.
27. Andrews, S.P.; Ball, M.; Wierschem, F.; Cleator, E.; Oliver, S.; Högenauer, K.; Simic, O.; Antonello, A.; Hüniger, U.; Smith, M.D.; Ley, S.V. Total synthesis of five thapsigargins: Guaianolide natural products exhibiting sub-nanmolar SERCA inhibition. Chem. A Eur. J., 2007, 13(20), 5688-5712.
28. Andersen, A.; Lauridsen, A.; Christensen, S.B. Radio- and Fluorescence-labelling of Tahpsigargin, a Selective Inhibitor of Microsomal Calcium-ATPase. J. Label. Compound. Radiopharm., 1992, 31(3), 199-206.
29. Jakobsen, C.M.; Denmeade, S.R.; Isaacs, J.T.; Gady, A.; Olsen, C.E.; Christensen, S.B. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J. Med. Chem., 2001, 44(26), 4696-4703.
30. Christensen, S.B.; Larsen, I.K.; Rasmussen, U.; Christophersen, C. Thapsigargin and thapsigargicin: two histamine liberating sesquiterpene lactones from Thapsia garganica. X-ray analysis of the 7,11-epoxide of thapsigargin. J. Org. Chem., 1982, 47(4), 649-652.
31. 2+ Pump Inhibitor Thapsigargin. Acta Chem. Scand., 1994, 48(4), 340-346.
32. Nielsen, S.F.; Thastrup, O.; Pedersen, R.; Olsen, C.E.; Christensen, S.B. Structure-activity relationships of analogues of thapsigargin modified at O-11 and O-12. J. Med. Chem., 1995, 38(2), 272-276.
33. 2+-ATPase inhibitory activity of a locked analog of thapsigargin. Bioorg. Med. Chem. Lett., 1994, 4(5), 657-660.
34. Oliver, S.F.; Högernauer, K.; Simic, O.; Antonello, A.; Smith, M.D.; Ley, S.V. A route to the thapsigargins from (S)-carvone providing a substrate-controlled total synthesis of trilobolide, nortrilobolide, and thapsiviollosin F. Angew. Chem. Int. Ed., 2003, 42(48), 5996-6000.
35. Ley, S.V.; Antonello, A.; Balskus, E.P.; Booth, D.T.; Christensen, S.B.; Cleator, E.; Gold, H.; Hogenauer, K.; Hunger, U.; Myers, R.M.; Oliver, S.F.; Simic, O.; Smith, M.D.; Sohoel, H.; Woolford, A.J.A. Synthesis of the thapsigargins. Proc. Natl. Acad. Sci. USA, 2004, 101(33), 12073-12078.
36. Ball, M.; Andrews, S.P.; Wierschem, F.; Cleator, E.; Smith, M.D.; Ley, S.V. Total synthesis of thapsigargin, a potent SERCA pump inhibitor. Org. Lett., 2007, 9(4), 663-666.
37. Sohoel, H.; Liljefors, T.; Ley, S.V.; Oliver, S.F.; Antonello, A.; Smith, M.D.; Olsen, C.E.; Isaacs, J.T.; Christensen, S.B. Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin. J. Med. Chem., 2005, 48(22), 7005-7011.
38. Rasmussen, U.; Christensen, S.B.; Sandberg, F. Thapsigargin and Thapsigargicin, Two New Histamine Liberators from Thapsia garganica L. Acta Pharm. Suec., 1978, 15(2), 133-140.
39. Denmeade, S.R.; Jakobsen, C.M.; Janssen, S.; Khan, S.R.; Garrett, E.S.; Lilja, H.; Christensen, S.B.; Isaacs, J.T. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J. Natl. Cancer Inst., 2003, 95(13), 990-1000.
40. Hakii, H.; Fujiki, H.; Suganuma, M.; Nakayasu, M.; Tahira, T.; Sugimura, T.; Scheuer, P.J.; Christensen, S.B. Thapsigargin, a histamine secretagogue, is a non-12-O- tetradecanoylphorbol-13-acetate (TPA) type tumor promoter in two- stage mouse skin carcinogenesis. J. Cancer Res. Clin. Oncol., 1986, 111(3), 177-181.
41. Mikkelsen, E.O.; Thastrup, O.; Christensen, S.B. Effects of thapsigargin in isolated rat thoracic aorta. Pharmacol. Toxicol., 1988, 62(1), 7-11.
42. Mikkelsen, E.O.; Poulsen, S.H.; Christensen, S.B. Comparison of the effects of thapsigargin and BAY K 8644 on spontaneous mechanical activity in rat portal vein and contractile responses of rat cardiac muscle. Pharmacol. Toxicol., 1992, 70(2), 152-156.
43. Patkar, S.A.; Rasmussen, U.; Diamant, B. On the mechanism of histamine release induced by thapsigargin from Thapsia garganica L. Agents Actions, 1979, 9(1), 53-57.
44. Ali, H.; Christensen, S.B.; Foreman, J.C.; Pearce, F.L.; Piotrowski, W.; Thastrup, O. The ability of thapsigargin and thapsigargicin to activate cells involved in the inflammatory response. Br. J. Pharmacol., 1985, 85(3), 705-712.
45. Ohuchi, K.; Sugawara, T.; Watanabe, M.; Hirasawa, N.; Tsurufuji, S.; Fujiki, H.; Sugimura, T.; Christensen, S.B. Stimulation of arachidonic acid metabolism in rat peritoneal macrophages by thapsigargin, a non-(12-O-tetradecanoylphorbol-13- acetate) (TPA)-type tumor promoter. J. Cancer Res. Clin. Oncol., 1987, 113(4), 319-324.
46. Ohuchi, K.; Sugawara, T.; Watanabe, M.; Hirasawa, N.; Tsurufuji, S.; Fujiki, H.; Christensen, S.B.; Sugimura, T. Analysis of the stimulative effect of thapsigargin, a non-TPA- type tumour promoter, on arachidonic acid metabolism in rat peritoneal macrophages. Br. J. Pharmacol., 1988, 94(3), 917-923.
47. Ohuchi, K.; Hirasawa, N.; Takahashi, C.; Watanabe, M.; Tsurufuji, S.; Fujiki, H.; Suganuma, M.; Hakii, H.; Sugimura, T.; Christensen, S.B. Synergistic stimulation of histamine release from rat peritoneal mast cells by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters. Biochim. Biophys. Acta, 1986, 887(1), 94-99.
48. Furuya, Y.; Lundmo, P.; Short, A.D.; Gill, D.L.; Isaacs, J.T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 1994, 54(23), 6167-6175.
49. Furuya, Y.; Isaacs, J.T. Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation. Prostate, 1994, 25(6), 301-309.
50. Lin, X.S.; Denmeade, S.R.; Cisek, L.; Isaacs, J.T. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate, 1997, 33(3), 201-207.
51. Jensen, A.M.L.; Sorensen, T.L.; Olesen, C.; Moller, J.V.; Nissen, P. Modulatory and catalytic modes of ATP binding by the calcium pump. EMBO J., 2006, 25(11), 2305-2314.
52. Sorensen, T.L.; Moller, J.V.; Nissen, P. Phosphoryl transfer and calcium ion occlusion in the calcium pump. Science, 2004, 304(5677), 1672-1675.
53. Olesen, C.; Picard, M.; Winther, A.M.; Gyrup, C.; Morth, J.P.; Oxvig, C.; Møller, J.V.; Nissen, P. The structural basis of calcium transport by the calcium pump. Nature, 2007, 450(7172), 1036-1042.
54. 2+-ATPase. Proc. Natl. Acad. Sci. USA, 1990, 87(7), 2466-2470.
55. Davidson, G.A.; Varhol, R.J. Kinetics of thapsigargin-Ca(2+)-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J. Biol. Chem., 1995, 270(20), 11731-11734.
56. de Bruin, E.C.; Medema, J.P. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev., 2008, 34(8), 737-749.
57. 2+ influx. Nature, 1993, 364(6440), 809-814.
58. + current by means of a phosphatase and a diffusible messenger. Nature, 1993, 364(6440), 814-818.
59. Taylor, C.W. Store-operated Ca2+ entry: A STIMulating stOrai. Trends Biochem. Sci., 2006, 31(11), 597-601.
60. Luik, R.M.; Wang, B.; Prakriya, M.; Wu, M.M.; Lewis, R.S. Oligomerization of STIM1 couples ER calcium depletion to CRAC channel activation. Nature, 2008, 454(7203), 538-542.
61. Tombal, B.; Weeraratna, A.T.; Denmeade, S.R.; Isaacs, J.T. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate, 2000, 43(4), 303-317.
62. Li, N.; Zheng, L.; Lin, P.; Danielpour, D.; Pan, Z.; Ma, J. Overexpression of Bax induces down-regulation of store-operated calcium entry in prostate cancer cells. J. Cell Physiol., 2008, 216(1), 172-179.
63. Scorrano, L.; Korsmeyer, S.J. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem. Biophys. Res. Commun., 2003, 304(3), 437-444.
64. Cory, S.; Adams, J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2(9), 647-656.
65. Wei, M.C.; Zong, W.X.; Cheng, E.H.Y.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacCregor, G.R.; Thompson, C.B.; Korsmeyer, S.J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science, 2001, 292(5517), 727-730.
66. Xu, C.; Ma, H.L.; Inesi, G.; Al-Shawi, M.K.; Toyoshima, C. Specific structural requirements for the inhibitory effect of thapsigargin on the Ca2+ ATPase SERCA. J. Biol. Chem., 2004, 279(17), 17973-17979.
67. Sagara, Y.; Inesi, G. Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. J. Biol. Chem., 1991, 266(21), 13503-13506.
68. Bobe, R.; Bredoux, R.; Corvazier, E.; Martin, V.; Gelebart, P.; Lacabaratz-Porret, C.; Launay, S.; Fanchaouy, M.; Dally, S.; Chaabane, C.; Kovacs, T.; Enouf, J. Sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) isoforms: 1998: 5 proteins; 2005: 14 proteins. Curr. Top. Biochem. Res., 2005, 7(1), 1-16.
69. Wootton, L.L.; Michelangeli, F. The effects of the phenylalanine 256 to valine mutation on the sensitivity of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) Ca2+ pump isoforms 1, 2, and 3 to thapsigargin and other inhibitors. J. Biol. Chem., 2006, 281(11), 6970-6976.
70. Olesen, C.; Sorensen, T.L.M.; Nielsen, R.C.; Moller, J.V.; Nissen, P. Dephosphorylation of the calcium pump coupled to counterion occlusion. Science, 2004, 306(5705), 2251-2255.
71. 2+-ATPase: A computational docking study. Proteins, 2004, 56(3), 595-604.
72. Olsson, A.Y.; Bjartell, A.; Lilja, H.; Lundwall, A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int. J. Cancer, 2005, 113(2), 290-297.
73. Otto, A.; Bar, J.; Birkenmeier, G. Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J. Urol., 1998, 159(1), 297-303.
74. Darson, M.F.; Pacelli, A.; Roche, P.; Rittenhouse, H.G.; Wolfert, R.L.; Saeid, M.S.; Young, C.Y.; Klee, G.G.; Tindall, D.J.; Bostwick, D.G. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology, 1999, 53(5), 939-944.
75. Darson, M.F.; Pacelli, A.; Roche, P.; Rittenhouse, H.G.; Wolfert, R.L.; Young, C.Y.; Klee, G.G.; Tindall, D.J.; Bostwick, D.G. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology, 1997, 49(6), 857-862.
76. Herrala, A.M.; Porvari, K.S.; Kyllonen, A.P.; Vihko, P.T. Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer, 2001, 92(12), 2975-2984.
77. Lintula, S.; Stenman, J.; Bjartell, A.; Nordling, S.; Stenman, U.H. Relative concentrations of hK2/PSA mRNA in benign and malignantt prostatic tissue. Prostate, 2005, 63(4), 324-329.
78. Christensson, A.; Laurell, C.B.; Lilja, H. Enzymatic-activity of prostate-specific antigen and its reactions with extracellular serine proteinase-inhibitors. Eur. J. Biochem., 1990, 194(3), 755-763.
79. Lilja, H.; Christensson, A.; Dahlen, U.; Matikainen, M.T.; Nilsson, O.; Pettersson, K.; Lovgren, T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem., 1991, 37(9), 1618-1625.
80. Lovgren, J.; Airas, K.; Lilja, H. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur. J. Biochem., 1999, 262(3), 781-789.
81. Mikolajczyk, S.D.; Millar, L.S.; Kumar, A.; Saedi, M.S. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate, 1998, 34(1), 44-50.
82. Lilja, H.; Abrahamsson, P.A.; Lundwall, A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J. Biol. Chem., 1989, 264(3), 1894-1900.
83. Robert, M.; Gibbs, B.F.; Jacobson, E.; Gagnon, C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/ semenogelin I. Biochemistry, 1997, 36(13), 3811-3819.
84. Sohoel, H.; Jensen, A.M.; Moller, J.V.; Nissen, P.; Denmeade, S.R.; Isaacs, J.T.; Olsen, C.E.; Christensen, S.B. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg. Med. Chem., 2006, 14(8), 2810-2815.
85. Denmeade, S.R.; Lou, W.; Lovgren, J.; Malm, J.; Lilja, H.; Isaacs, J.T. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res., 1997, 57(21), 4924-4930.
86. Denmeade, S.R.; Nagy, A.; Gao, J.; Lilja, H.; Schally, A.V.; Isaacs, J.T. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res., 1998, 58(12), 2537-2540.
87. Garsky, V.M.; Lumma, P.K.; Feng, D.M.; Wai, J.; Ramjit, H.G.; Sardana, M.K.; Oliff, A.; Jones, R.E.; Feo-Jones, D.; Freidinger, R.M. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J. Med. Chem., 2001, 44(24), 4216-4224.
88. DeFeo-Jones, D.; Garsky, V.M.; Wong, B.K.; Feng, D.-M.; Bolyar, T.; Haskell, K.; Kiefer, D.M.; Leander, K.; McAvoy, E.; Lumma, P.; Wai, J.; Senderpak, E.T.; Motzel, S.L.; Keenan, K.; van Zwieten, M.; Lin, J.H.; Freidinger, R.; Huff, J.; Oliff, A.; Jones, R.E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen slelctively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med., 2000, 6(11), 1248-1252.
89. Kumar, S.K.; Roy, I.; Anchoori, R.K.; Fazli, S.; Maitra, A.; Beachy, P.A.; Khan, S.R. Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. Bioorg. Med. Chem., 2008, 16(6), 2764-2768.
90. Kumar, S.K.; Williams, S.A.; Isaacs, J.T.; Denmeade, S.R.; Khan, S.R. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg. Med. Chem., 2007, 15(14), 4973-4984.
91. Brady, S.F.; Pawluczyk, J.M.; Lumma, P.K.; Feng, D.M.; Wai, J.M.; Jones, R.; Feo-Jones, D.; Wong, B.K.; Miller-Stein, C.; Lin, J.H.; Oliff, A.; Freidinger, R.M.; Garsky, V.M. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J. Med. Chem., 2002, 45(21), 4706-4715.
92. Jones, G.B.; Mitchell, M.O.; Weinberg, J.S.; D'Amigo, A.V.D.; Bubley, G.J. Towards enzyme activated antiprostatic agents. Bioorg. Med. Chem. Lett., 2000, 10(17), 1987-1989.
93. Janssen, S.; Jakobsen, C.M.; Rosen, D.M.; Ricklis, R.M.; Reinecke, U.; Christensen, S.B.; Lilja, H.; Denmeade, S.R. Screening a combinatoril peptide library to develop a human glandular kallikrein-2 (hK2) activated prodrug as targeted therapy for prostate cancer. Mol. Cancer Ther., 2004, 3(11), 1439-1450.